Literature DB >> 3729976

Formation of an inactive cytochrome P-450Fe(II)-metabolite complex after administration of amiodarone in rats, mice and hamsters.

D Larrey, M Tinel, P Letteron, J Geneve, V Descatoire, D Pessayre.   

Abstract

Administration of amiodarone hydrochloride (50-150 mg/kg i.p. daily) to rats, mice or hamsters resulted in the in vivo formation of a cytochrome P-450Fe(II)-amiodarone metabolite complex absorbing at 453 nm, unable to bind CO and biologically inactive. In rats, the amount of complex present in hepatic microsomes was small 24 hr after administration of a single dose of amiodarone (100 mg/kg i.p.) but was increased 2.5-times by pretreatment with phenobarbital and 8-times by pretreatment with dexamethasone phosphate. In addition, the complex increased linearly with time as the doses of amiodarone were repeated daily. When both enhancing factors were combined (treatment for 3 days with both dexamethasone and amiodarone), the amount of complex present in liver microsomes reached 0.78 nmol/mg protein or 40% of total cytochrome P-450 in rats. In these rats, in vitro disruption of the complex with potassium ferricyanide suppressed its Soret peak at 453 nm, increased by 70% the CO-binding spectrum of dithionite-reduced microsomes, and restored several monooxygenase activities. The 453 nm-absorbing complex was also formed in vitro upon incubation of amiodarone or N-desethylamiodarone with NADPH, EDTA and microsomes from dexamethasone-treated rats. The formation of the complex was smaller with microsomes from phenobarbital-treated rats and was not detected with microsomes from control rats. We conclude that amiodarone forms an inactive cytochrome P-450Fe(II)-metabolite complex in rats, mice and hamsters.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3729976     DOI: 10.1016/0006-2952(86)90594-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions.

Authors:  K Ohyama; M Nakajima; M Suzuki; N Shimada; H Yamazaki; T Yokoi
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

2.  Differences in hepatic drug accumulation and enzyme induction after chronic amiodarone feeding of two rat strains: role of the hydroxylator phenotype?

Authors:  M Pirovino; U Honegger; O Müller; T Zysset; A Küpfer; M Tinel; D Pessayre
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

3.  Effect of amiodarone and desethylamiodarone on the pharmacokinetics of antipyrine in the rat.

Authors:  C K Svensson; L L Liu; P W Knowlton
Journal:  Pharm Res       Date:  1987-06       Impact factor: 4.200

Review 4.  The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.

Authors:  Brooke M VandenBrink; Nina Isoherranen
Journal:  Curr Opin Drug Discov Devel       Date:  2010-01

5.  Cytochrome P-450 metabolic-intermediate complex formation with a series of diphenhydramine analogues.

Authors:  A Bast; A J Valk; H Timmerman
Journal:  Agents Actions       Date:  1990-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.